LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) OverviewTrack LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s EBIT ($-360M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2024
Trailing 12 months ending Mar 31, 2024
The latest EBIT for YSBPW is $-360M as of March 2024. That is below the sector sector average of $-27M. Investors often review this figure alongside LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, YSBPW currently prints $-360M for EBIT, while the sector average sits near $-27M. That is roughly 1230.2% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s growth, margins, and balance sheet.
A EBIT figure of $-360M for YSBPW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-27M. Explore the charts below for those layers of context.
After noting YSBPW's EBIT ($-360M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
